What drives us is knowing the fact that we can make a meaningful difference in our patients’ lives.
Our Core Values
What drives us is knowing the fact that we can make a meaningful difference in our patients’ lives.
We have to be creative and constantly think about, how we can prevent the next epidemic. Prevention over cure is a lot easier for everyone.
We also make every effort so that our products are available to any and every patient in need because our health is priceless.
Our Mission
The representation of infectious diseases has become increasingly critical, especially in the wake of the COVID-19 pandemic. During this global crisis, we witnessed quarantines, sacrifices by front-liners, and the strain on government administrations. Citizens across countries grappled with panic and uncertainty. Our mission is to fortify public health defenses against any formidable infectious disease. Recognizing that prevention strategies for a single viral pathogen may not suffice, we focus our efforts on developing broad-spectrum antiviral prophylaxis and therapeutics. By doing so, we aim to safeguard communities and mitigate the impact of future outbreaks.
ABTS is a U.S. subsidiary of ABION with offices and labs in Seoul, Boston (CIC), and Irvine offices.
ABN101:
Broad Spectrum Anti-Viral Preventative / Treatment
Why Broad Spectrum?
- Infuenza
- COVID-19
- MERS
- RSV
- Better Treatment for Multiple Sclerosis
ABN101 is significant advancement in personal health safety It effects all of us especially for travelers and those exposed to large crowds and spreads quickly.
The in-vitro efficacy against a range of respiratory diseases including influenza, COVID-19 and its mutated versions, other SAR-COVID viruses, MERS, RSV, and even its effectiveness in multiple sclerosis is quite remarkable and much less costly.
- Clinical Trials
After successful in-vitro tests combined, with years of research and tests, the next step involves clinical trials to confirm safety and efficacy in humans. This often involves multiple phases and a significant investment of time and resources.
- Regulatory Approval
Gaining approval from health regulatory authorities like the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency) is crucial. This process includes a thorough review of clinical trial data and other relevant information.
- Market Strategy
A clear strategy for market introduction is important. This includes identifying target markets, distribution channels, and marketing tactics. It could have been easier to test one inhibition at a time but given the broad potential application of ABN101, defining the initial focus areas and gradually expanding could be a strategy.
- Manufacturing and Distribution
Ensuring the ability to manufacture at scale and establishing a reliable distribution network is key to the successful deployment of ABN101.
- Continual Research and Development
Ongoing R&D to stay ahead of evolving pathogens, especially in the context of respiratory diseases and viruses, will be essential.
- Education and Awareness
Educating the public, healthcare professionals, and potential users about the benefits and proper use of your device is important for adoption. Having partnership to wide distribution is key to stop the spreading of the next pandemic.
- Partnerships
Collaborating with healthcare providers, governments, and international health organizations could broaden the reach and impact of your product.
In COVID19 PANDEMIC
Total 8.4 Million
Confirmed Cases
USD 28 Trillion
ECONOMIC LOSS
Total 1.88 Million
Deaths
Pandamic Occurs
No Drug Period
(approx. 1 Year)
Vaccine Drug Supply
ABN101 introduction
Advantages of ABN101 better than other interferon products
High Affinity
Same potency with a smaller amount
Productivity Optimization
Productivity improved by
640-fold
Formulation Optimization
Formulation for viral respiratory diseases
ABN101 Broad spectrum anti-viral therapeutics
Dry powder formulation
The production of Interferon-beta in dry powder formation, ABN101 is the first-in-class technology and developed in the appropriate inhaler at best The applicable manner in ABN101 dry powder development potentially regulates RNA respiratory virus variation, reconstructing new paradigm of therapy
Prophylaxis and Vaccine
- As lesson learned from COVID-19, we must respond to treat emerging viral pathogens as quickly as possible, but the vaccine is not the one. Prophylaxis with broad-spectrum antiviral drug can be a better benefits than vaccine. ABN101 can be the best prophylactic agent against emerging pathogens as well as virus infection
Impact on livelihood
COVID-19 pandemic has cause lifestyle changes and economic burden drastically. People got impoverished while inflation rate pivoted. ABTS recognizes those exacerbation and improvise ABN101 to potentially rephrase situation before the COVID-19 pandemic.
Costs Benefits
- Through the help of our partners and our technology, we were able to save costs by 80X. The active ingredient here is the Interferon Bio-beta.
- While we scale up production, costs will continue to decline. In addition, the medication stays in your body longer. This means one dose will last xxx longer that the previous. Instead of in-haling 2X a week, it will be once.
- Multiple sclerosis patients pay extreme amounts of money and trips to the hospital become a pain where you lose the will to be active again. Secondly, if we combine all the waste from wet naps, hand sanitizers, masks and other anti-bacterial items that go to waste, we could be saving multi-billions if not more instead of saving trash which causes environmental waste.
